CHEMOSAT®: New data for patients with metastatic ocular melanoma (mOM)

Oral Presentation from Phase 3 FOCUS Trial of CHEMOSAT® at the American Society of Clinical Oncology (ASCO) Annual Meeting

Wedel, Germany (26.05.2021)  CHEMOSAT® , marketed by medac, is a minimally invasive delivery system for the administration of high-dose chemotherapy directly to the liver while controlling systemic exposure. Predominantly CHEMOSAT® is used to treat patients with unresectable liver-dominant metastatic ocular melanoma (mOM).

The manufacturer of CHEMOSAT® Delcath Systems, Inc. announced an oral presentation at the ASCO Annual Meeting about the new positive preliminary data from the Phase 3 FOCUS Trial:
“Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial” presented by Jonathan S. Zager, MD FACS is taking place on June 4, 9:00 AM (EDT)

Dr. Zager will be presenting on behalf of the Principal Investigators that participated in the FOCUS trial.

FOCUS is an open label, single-arm, multi-center trial, conducted in 23 centres in USA and EU sponsored by Delcath Systems, Inc. The trial is intended to evaluate the efficacy, safety and pharmacokinetics of melphalan hydrochloride in combination with CHEMOSAT® in patients with hepatic-dominant ocular melanoma. In the oral presentation at the ASCO Annual Meeting we are expecting new positive data regarding the prespecified endpoints overall response rate, median progression free survival and disease control rate.

CHEMOSAT®: A liver-directed chemotherapy

CHEMOSAT® is a minimally invasive delivery system for the administration of high-dose chemotherapy (melphalan hydrochloride) directly to the liver while controlling systemic exposure and associated side effects to treat liver metastases, usually resulting from ocular melanoma.

Liver dominant metastatic ocular melanoma is a very rare disease for which no standard therapy is available to date. CHEMOSAT® with melphalan has already shown to be a safe and effective treatment for patients with unresectable liver metastases in various indications for small patient populations.

Since 2019 Delcath Systems, Inc. has exclusively licensed medac to sell and market this certified medical device in the EU, UK, Norway, Liechtenstein and Switzerland. This means to medac a very promising addition to the already well established product portfolio in Oncology.